Evolus Inc (NASDAQ:EOLS) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $31.40.
A number of equities analysts have commented on the company. Zacks Investment Research downgraded Evolus from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Stifel Nicolaus initiated coverage on Evolus in a report on Monday, January 28th. They set a “buy” rating and a $27.00 target price on the stock.
In other Evolus news, Director Vikram Malik purchased 7,800 shares of the company’s stock in a transaction that occurred on Monday, December 17th. The stock was purchased at an average price of $13.04 per share, with a total value of $101,712.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Corp Alphaeon sold 573,888 shares of the stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $14.00, for a total transaction of $8,034,432.00. The disclosure for this sale can be found here. In the last three months, insiders have acquired 17,147 shares of company stock valued at $228,880.
NASDAQ:EOLS traded down $0.56 during mid-day trading on Wednesday, reaching $26.00. The stock had a trading volume of 1,492,600 shares, compared to its average volume of 1,461,977. The company has a market capitalization of $776.25 million and a price-to-earnings ratio of -96.30. Evolus has a 1-year low of $6.75 and a 1-year high of $39.50.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Featured Article: What is a Roth IRA?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.